HKSE - Delayed Quote HKD

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)

Compare
189.100 -4.000 (-2.07%)
At close: 4:08 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Junyou Ge President, CEO, COO, GM & Executive Director 3.9M -- 1972
Mr. Zejian Zhou CFO & Joint Company Secretary -- -- 1982
Mr. Yong Guo Deputy GM, Chief Commercial Officer & Chief Marketing Officer -- -- 1970
Mr. Yi Feng Deputy GM, Chief Strategy Officer & Senior VP -- -- 1966
Dr. Xiangyang Tan Deputy GM and Chief Scientific Officer of Biologics' Research & Development -- -- 1963
Dr. Xiaoping Jin Deputy GM & Chief Medical Officer -- -- 1978
Ms. Wai Sum Fung A.C.I.S., A.C.S. Joint Company Secretary -- -- 1983

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park Wenjiang District
Chengdu
China
https://kelun-biotech.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
1,542

Description

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Corporate Governance

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 19, 2024 at 10:59 AM UTC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Earnings Date

Recent Events

Related Tickers